|
1
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142(1264–1273): e12612012.
|
|
2
|
Hatzaras I, Bischof DA, Fahy B, Cosgrove D
and Pawlik TM: Treatment options and surveillance strategies after
therapy for hepatocellular carcinoma. Ann Surg Oncol. 21:758–766.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen MF, Hwang TL, Jeng LB, Wang CS, Jan
YY and Chen SC: Postoperative recurrence of hepatocellular
carcinoma. Two hundred five consecutive patients who underwent
hepatic resection in 15 years. Arch Surg. 129:738–742. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chao Y, Chung YH, Han G, Yoon JH, Yang J,
Wang J, Shao GL, Kim BI and Lee TY: The combination of
transcatheter arterial chemoembolization and sorafenib is well
tolerated and effective in Asian patients with hepatocellular
carcinoma: Final results of the START trial. Int J Cancer.
136:1458–1467. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY,
Kang YK, Shin YM, Kim KM, Lim YS and Lee HC: Sorafenib alone versus
sorafenib combined with transarterial chemoembolization for
advanced-stage hepatocellular carcinoma: Results of propensity
score analyses. Radiology. 269:603–611. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hua L, Hu B, Yan D, Liu J, Shen Y, Zhao F,
Shen C, Chen B and Cui X: Upregulated expression of
Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib
Resistance in Hepatocellular Carcinoma. Pathol Res Pract.
213:688–697. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qin S, Bai Y, Lim HY, Thongprasert S, Chao
Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, et al:
Randomized, multicenter, open-label study of oxaliplatin plus
fluorouracil/leucovorin versus doxorubicin as palliative
chemotherapy in patients with advanced hepatocellular carcinoma
from Asia. J Clin Oncol. 31:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zaanan A, Williet N, Hebbar M, Dabakuyo
TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S,
Bonnetain F, et al: Gemcitabine plus oxaliplatin in advanced
hepatocellular carcinoma: A large multicenter AGEO study. J
Hepatol. 58:81–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gobel T, Blondin D, Kolligs F, Bolke E and
Erhardt A: Current therapy of hepatocellular carcinoma with special
consideration of new and multimodal treatment concepts. Dtsch Med
Wochenschr. 138:1425–1430. 2013.(In German). PubMed/NCBI
|
|
12
|
Yang JX, Luo Y, Qiu HM and Tang WX:
Characterization and resistance mechanisms of cisplatin-resistant
human hepatocellular carcinoma cell line. Saudi Med J. 30:35–40.
2009.PubMed/NCBI
|
|
13
|
Song K, Yi J, Shen X and Cai Y: Genetic
polymorphisms of glutathione S-transferase genes GSTM1, GSTT1 and
risk of hepatocellular carcinoma. PLoS One. 7:e489242012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Pietro G, Magno LA and Rios-Santos F:
Glutathione S-transferases: An overview in cancer research. Expert
Opin Drug Metab Toxicol. 6:153–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Verrier F, Deniaud A, Lebras M, Métivier
D, Kroemer G, Mignotte B, Jan G and Brenner C: Dynamic evolution of
the adenine nucleotide translocase interactome during
chemotherapy-induced apoptosis. Oncogene. 23:8049–8064. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ding ZB, Shi YH, Zhou J, Qiu SJ, Xu Y, Dai
Z, Shi GM, Wang XY, Ke AW, Wu B and Fan J: Association of autophagy
defect with a malignant phenotype and poor prognosis of
hepatocellular carcinoma. Cancer Res. 68:9167–9175. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin S and White E: Role of autophagy in
cancer: Management of metabolic stress. Autophagy. 3:28–31. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
King FW, Fong S, Griffin C, Shoemaker M,
Staub R, Zhang YL, Cohen I and Shtivelman E: Timosaponin AIII is
preferentially cytotoxic to tumor cells through inhibition of mTOR
and induction of ER stress. PLoS One. 4:e72832009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tew KD: Glutathione-associated enzymes in
anticancer drug resistance. Cancer Res. 54:4313–4320.
1994.PubMed/NCBI
|
|
20
|
Ang WH, Khalaila I, Allardyce CS,
Juillerat-Jeanneret L and Dyson PJ: Rational design of platinum(IV)
compounds to overcome glutathione-S-transferase mediated drug
resistance. J Am Chem Soc. 127:1382–1383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Townsend DM and Tew KD: The role of
glutathione-S-transferase in anti-cancer drug resistance. Oncogene.
22:7369–7375. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang T, Zheng ZM, Li XN, Li ZF, Wang Y,
Geng YF, Bai L and Zhang XB: MiR-223 modulates multidrug resistance
via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp
Biol Med (Maywood). 238:1024–1032. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao N, Wang R, Zhou L, Zhu Y, Gong J and
Zhuang SM: MicroRNA-26b suppresses the NF-κB signaling and enhances
the chemosensitivity of hepatocellular carcinoma cells by targeting
TAK1 and TAB3. Mol Cancer. 13:352014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou Z, Deng H, Yan W, Luo M, Tu W, Xia Y,
He J, Han P, Fu Y and Tian D: AEG-1 promotes anoikis resistance and
orientation chemotaxis in hepatocellular carcinoma cells. PLoS One.
9:e1003722014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qu Z, Wu J, Wu J, Luo D, Jiang C and Ding
Y: Exosomes derived from HCC cells induce sorafenib resistance in
hepatocellular carcinoma both in vivo and in vitro. J Exp Clin
Cancer Res. 35:1592016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu X, Liu RF, Zhang X, Huang LY, Chen F,
Fei QL and Han ZG: DLK1 as a potential target against cancer
stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther.
11:629–638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen X, Lingala S, Khoobyari S, Nolta J,
Zern MA and Wu J: Epithelial mesenchymal transition and hedgehog
signaling activation are associated with chemoresistance and
invasion of hepatoma subpopulations. J Hepatol. 55:838–845. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding ZB, Hui B, Shi YH, Zhou J, Peng YF,
Gu CY, Yang H, Shi GM, Ke AW, Wang XY, et al: Autophagy activation
in hepatocellular carcinoma contributes to the tolerance of
oxaliplatin via reactive oxygen species modulation. Clin Cancer
Res. 17:6229–6238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke
AW, Wang XY, Dai Z, Peng YF, Gu CY, et al: Targeting autophagy
enhances sorafenib lethality for hepatocellular carcinoma via ER
stress-related apoptosis. Autophagy. 7:1159–1172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mizushima N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell. 147:728–741. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moreau K, Luo S and Rubinsztein DC:
Cytoprotective roles for autophagy. Curr Opin Cell Biol.
22:206–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Hou N, Faried A, Tsutsumi S,
Takeuchi T and Kuwano H: Inhibition of autophagy by 3-MA enhances
the effect of 5-FU-induced apoptosis in colon cancer cells. Ann
Surg Oncol. 16:761–771. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Amaravadi RK, Yu D, Lum JJ, Bui T,
Christophorou MA, Evan GI, Thomas-Tikhonenko A and Thompson CB:
Autophagy inhibition enhances therapy-induced apoptosis in a
Myc-induced model of lymphoma. J Clin Invest. 117:326–336. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tian F, Deguchi K, Yamashita T, Ohta Y,
Morimoto N, Shang J, Zhang X, Liu N, Ikeda Y, Matsuura T and Abe K:
In vivo imaging of autophagy in a mouse stroke model. Autophagy.
6:1107–1114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Klionsky DJ, Abdalla FC, Abeliovich H,
Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M,
Agostinis P, Aguirre-Ghiso JA, et al: Guidelines for the use and
interpretation of assays for monitoring autophagy. Autophagy.
8:445–544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nourani MR, Azimzadeh S, Ghanei M and
Fooladi Imani AA: Expression of glutathione S-transferase variants
in human airway wall after long-term response to sulfur mustard. J
Recept Signal Transduct Res. 34:125–130. 2013. View Article : Google Scholar : PubMed/NCBI
|
